We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $2.8B
1-Year Est. Return 13.35%
This Fund
S&P 500
This Quarter Est. Return
+55.33%
1 Year Est. Return
+13.35%
3 Year Est. Return
+27.45%
5 Year Est. Return
+53.33%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
+$44.3M
Cap. Flow
-$275M
Cap. Flow %
-20.27%
Top 10 Hldgs %
100%
Holding
25
New
–
Increased
2
Reduced
2
Closed
15

Top Buys

Rank Stock Value
1
LLYVK icon
Liberty Live Group Series C
LLYVK
+$7.68M

Top Sells

Rank Stock Value
1
QXO
QXO Inc
QXO
+$54.4M
2
LBRDK
Liberty Broadband Class C
LBRDK
+$45M
3
SWTX
SpringWorks Therapeutics
SWTX
+$32.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$28M
5
RVMD icon
Revolution Medicines
RVMD
+$24.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 62.81%
2 Industrials 33.61%
3 Communication Services 3.22%
4 Healthcare 0.35%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$725M 53.49%
1,173,500
+418,500
+55% +$239M
QXO
2
QXO Inc
QXO
$13.9B
$456M 33.61%
21,152,868
-3,315,292
-14% -$54.4M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$81.2B
$126M 9.31%
585,000
-900,000
-61% -$181M
LLYVK icon
4
Liberty Live Group Series C
LLYVK
$9.11B
$43.6M 3.22%
537,051
+104,156
+24% +$7.68M
SLDB icon
5
Solid Biosciences
SLDB
$1.1B
$4.68M 0.35%
961,251
– –
ANNA
6
AleAnna Inc
ANNA
$123M
$200K 0.01%
27,717
– –
ANNAW
7
AleAnna Inc Warrant
ANNAW
$8.12M
$115K 0.01%
490,000
– –
MNYWW
8
MoneyHero Ltd Warrants
MNYWW
$708K
$41.9K ﹤0.01%
895,000
– –
LSBPW
9
DELISTED
LakeShore Biopharma Warrants
LSBPW
$19.6K ﹤0.01%
489,999
– –
CLDI icon
10
Calidi Biotherapeutics
CLDI
$3.59M
$2.88K ﹤0.01%
65
– –
ARVN icon
11
Arvinas
ARVN
$614M
– –
-694,028
Closed -$4.87M
ASND icon
12
Ascendis Pharma A/S
ASND
$17.7B
– –
-179,872
Closed -$28M
CYTK icon
13
Cytokinetics
CYTK
$10.1B
– –
-309,948
Closed -$12.5M
EYPT icon
14
EyePoint Inc
EYPT
$395M
– –
-1,081,954
Closed -$5.86M
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.87B
– –
-656,587
Closed -$16.5M
LBRDK
16
DELISTED
Liberty Broadband Class C
LBRDK
– –
-529,240
Closed -$45M
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.28B
– –
-435,785
Closed -$17M
PRTA icon
18
Prothena Corp
PRTA
$504M
– –
-640,071
Closed -$7.92M
RLAY icon
19
Relay Therapeutics
RLAY
$4.17B
– –
-2,117,646
Closed -$5.55M
RNAM
20
DELISTED
Avidity Biosciences
RNAM
– –
-380,700
Closed -$11.2M
RVMD icon
21
Revolution Medicines
RVMD
$45B
– –
-691,260
Closed -$24.4M
SRPT icon
22
Sarepta Therapeutics
SRPT
$2.38B
– –
-157,555
Closed -$10.1M
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
– –
-728,602
Closed -$32.2M
XNCR icon
24
Xencor
XNCR
$1.98B
– –
-642,200
Closed -$6.83M
GATEW
25
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
– –
-735,000
Closed -$118K

Similar funds

MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
HFCIX
H&F Corporate Investors X San Francisco, California $2.8B AUM
PAI
Pittenger & Anderson Inc Lincoin, Nebraska $2.79B AUM 12.81% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
LIMS
Lasalle Investment Management Securities Baltimore, Maryland $2.81B AUM 16.57% 1-Year Est. Return
ECA
Encompass Capital Advisors New York $2.81B AUM 198.36% 1-Year Est. Return
EPM
Elm Partners Management Philadelphia, Pennsylvania $2.79B AUM 18.53% 1-Year Est. Return
PCP
Proficio Capital Partners Newton, Massachusetts $2.79B AUM 27.93% 1-Year Est. Return

Finepoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Finepoint Capital held 25 positions worth $1.36B, up 3.4% from $1.31B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Finepoint Capital withdrew a net $275M in Q2 2025, closing 15 positions and reducing 2 holdings. Its most notable exit was Liberty Broadband Class C, an estimated $45M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 63% of assets, up from 55% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Finepoint Capital added an estimated $7.68M to Liberty Live Group Series C.

  • Finepoint Capital added most to Liberty Live Group Series C in Q2 2025, an estimated $7.68M increase.
  • Finepoint Capital's biggest Q2 2025 reduction was QXO Inc, cutting an estimated $54.4M.
  • Finepoint Capital fully exited Liberty Broadband Class C in Q2 2025, selling an estimated $45M.
  • Finepoint Capital's ten largest holdings make up 100% of its $1.36B portfolio in Q2 2025.
  • Finepoint Capital opened 0 new positions and closed 15 in Q2 2025.
  • Finepoint Capital's portfolio value rose 3.4% quarter-over-quarter to $1.36B.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.